Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$111.23 +1.0%	$106.39	$72.21 ▼ $139.13	$5.48B	0.46	667,525 shs	371,948 shs
INSM Insmed	$104.61 +1.7%	$84.68	$60.40 ▼ $106.83	$19.85B	0.9	2.30 million shs	2.76 million shs
JAZZ Jazz Pharmaceuticals	$116.01 +3.3%	$108.20	$95.49 ▼ $148.06	$7.02B	0.32	830,469 shs	637,213 shs
TEVA Teva Pharmaceutical Industries	$16.02 -0.2%	$17.09	$12.47 ▼ $22.80	$18.37B	0.6	10.32 million shs	12.73 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-1.97%	+1.58%	+5.78%	+5.41%	+33.00%
INSM Insmed	+0.96%	+7.00%	+4.19%	+46.54%	+32.79%
JAZZ Jazz Pharmaceuticals	+0.77%	+2.90%	+3.50%	+10.59%	+8.68%
TEVA Teva Pharmaceutical Industries	-2.32%	-3.64%	-5.61%	+19.55%	-6.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.6945 of 5 stars	4.5	1.0	4.5	2.2	4.2	0.6
INSM Insmed	3.8065 of 5 stars	2.5	4.0	4.3	2.1	1.7	0.6
JAZZ Jazz Pharmaceuticals	4.7986 of 5 stars	4.5	1.0	4.0	1.4	3.3	2.5
TEVA Teva Pharmaceutical Industries	3.8376 of 5 stars	4.6	4.0	0.0	1.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	54.94% Upside
INSM Insmed	3.00	Buy	$108.07	3.31% Upside
JAZZ Jazz Pharmaceuticals	2.93	Moderate Buy	$181.71	56.64% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	54.32% Upside

Current Analyst Ratings Breakdown

Latest AXSM, JAZZ, TEVA, and INSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	JAZZ Jazz Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$152.00
7/8/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $111.00
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/11/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $112.00
6/11/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
6/11/2025	INSM Insmed	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$99.00 ➝ $106.00
6/11/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $102.00
6/11/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$107.00 ➝ $119.00
6/11/2025	INSM Insmed	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$94.00 ➝ $109.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$432.16M	12.67	N/A	N/A	$1.18 per share	94.26
INSM Insmed	$363.71M	54.56	N/A	N/A	$1.60 per share	65.38
JAZZ Jazz Pharmaceuticals	$4.07B	1.73	$31.61 per share	3.67	$67.72 per share	1.71
TEVA Teva Pharmaceutical Industries	$16.54B	1.11	$3.28 per share	4.88	$4.74 per share	3.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	39.44	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/6/2025 (Estimated)
JAZZ Jazz Pharmaceuticals	$560.12M	$7.50	15.47	6.20	4.81	11.86%	26.62%	9.14%	7/30/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.09	0.97	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)

Latest AXSM, JAZZ, TEVA, and INSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
7/30/2025	Q2 2025	JAZZ Jazz Pharmaceuticals	-$5.61	N/A	N/A	N/A	$1.05 billion	N/A
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	N/A	N/A	N/A	$4.34 billion	N/A
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/6/2025	Q1 2025	JAZZ Jazz Pharmaceuticals	$4.65	$1.68	-$2.97	-$1.52	$984.16 million	$897.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
INSM Insmed	11.38	5.86	5.44
JAZZ Jazz Pharmaceuticals	1.28	3.38	2.97
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
INSM Insmed	N/A
JAZZ Jazz Pharmaceuticals	89.14%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.40%
INSM Insmed	3.00%
JAZZ Jazz Pharmaceuticals	4.30%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.21 million	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
JAZZ Jazz Pharmaceuticals	2,800	60.51 million	57.91 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

AXSM, JAZZ, TEVA, and INSM Headlines

Recent News About These Companies

Envestnet Asset Management Inc. Cuts Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 15 at 3:39 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Sold by Penserra Capital Management LLC

July 13 at 3:45 AM | marketbeat.com

TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?

July 11, 2025 | zacks.com

Teva Pharmaceutical (TEVA) Just Flashed a Statistically Viable Signal for Bullish Traders

July 10, 2025 | msn.com

Teva (TEVA) Receives a Buy from Leader Capital Markets

July 10, 2025 | theglobeandmail.com

Stock Traders Buy High Volume of Teva Pharmaceutical Industries Put Options (NYSE:TEVA)

July 9, 2025 | americanbankingnews.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Holdings Boosted by IFM Investors Pty Ltd

July 8, 2025 | marketbeat.com

Stock Traders Purchase Large Volume of Teva Pharmaceutical Industries Put Options (NYSE:TEVA)

July 7, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. ADR Stock Grades - Barron's

July 7, 2025 | barrons.com

Leader Capital Markets Keeps Their Buy Rating on Teva (TEVA)

July 7, 2025 | theglobeandmail.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Buy" from Brokerages

July 7, 2025 | americanbankingnews.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Buy" from Analysts

July 7, 2025 | marketbeat.com

Teacher Retirement System of Texas Reduces Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 6, 2025 | marketbeat.com

Cambridge Investment Research Advisors Inc. Purchases 41,600 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 5, 2025 | marketbeat.com

Harel Insurance Investments & Financial Services Ltd. Buys 22,044,407 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 4, 2025 | marketbeat.com

Straight Path Wealth Management Decreases Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 3, 2025 | marketbeat.com

WCM Investment Management LLC Increases Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 3, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Bought by DAVENPORT & Co LLC

July 3, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Purchased by Sumitomo Mitsui Trust Group Inc.

July 2, 2025 | marketbeat.com

Billionaire Stanley Druckenmiller Sold Palantir And Buying This Stock Instead

July 1, 2025 | 247wallst.com

Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen solid returns of 112% over the past three years

July 1, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM, JAZZ, TEVA, and INSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$111.23 +1.11 (+1.00%)

Closing price 03:59 PM Eastern

Extended Trading

$109.56 -1.67 (-1.50%)

As of 04:09 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Insmed NASDAQ:INSM

$104.61 +1.74 (+1.69%)

Closing price 03:59 PM Eastern

Extended Trading

$104.61 +0.00 (+0.00%)

As of 04:04 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Jazz Pharmaceuticals NASDAQ:JAZZ

$116.01 +3.71 (+3.30%)

Closing price 03:59 PM Eastern

Extended Trading

$115.05 -0.96 (-0.83%)

As of 04:07 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Teva Pharmaceutical Industries NYSE:TEVA

$16.02 -0.03 (-0.16%)

Closing price 03:59 PM Eastern

Extended Trading

$15.93 -0.09 (-0.53%)

As of 04:09 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time